Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024Newsfile Corp • 08/05/24
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid TumorBusiness Wire • 08/02/24
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma FranchiseNewsfile Corp • 06/03/24
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsGlobeNewsWire • 05/30/24
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor IndicationsNewsfile Corp • 05/30/24
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024Newsfile Corp • 05/01/24
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies TerminatedNewsfile Corp • 04/12/24
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the LancetNewsfile Corp • 03/27/24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma FranchiseNewsfile Corp • 02/27/24
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024Newsfile Corp • 02/21/24
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority ReviewNewsfile Corp • 01/31/24